Cargando…

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

BACKGROUND: Patients with inflammatory bowel disease who achieve remission with anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled data investigating this strategy. The primary study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaparro, María, Donday, María G., Barreiro-de Acosta, Manuel, Domènech, Eugeni, Esteve, María, García-Sánchez, Valle, Nos, Pilar, Panés, Julián, Martínez, Concepción, Gisbert, Javier P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832302/ https://www.ncbi.nlm.nih.gov/pubmed/35154384 http://dx.doi.org/10.1177/1756284819874202

Ejemplares similares

Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
por: Barreiro‐de Acosta, Manuel, et al.
Publicado: (2021)

The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU
por: Chaparro, María, et al.
Publicado: (2021)

Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?
por: Kim, Byungsoo, et al.
Publicado: (2019)

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
por: Chaparro, María, et al.
Publicado: (2019)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Management and outcomes of patients with Crohn’s disease with first vs multiple surgeries: results from the PRACTICROHN study
por: Iborra, Marisa, et al.
Publicado: (2019)

Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease
por: Casadó-Llombart, Sergi, et al.
Publicado: (2022)

Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review
por: Aldars-García, Laila, et al.
Publicado: (2021)

Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis
por: Baldan-Martin, Montse, et al.
Publicado: (2023)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
por: Marsal, Jan, et al.
Publicado: (2022)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease
por: Aldars-García, Laila, et al.
Publicado: (2021)

Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain
por: Calvet, Xavier, et al.
Publicado: (2022)

The Genetic Diversity and Dysfunctionality of Catalase Associated with a Worse Outcome in Crohn’s Disease
por: Iborra, Marisa, et al.
Publicado: (2022)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
por: Cañete, Fiorella, et al.
Publicado: (2020)

Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease
por: Fernández-Tomé, Samuel, et al.
Publicado: (2021)

The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review
por: Aldars-García, Laila, et al.
Publicado: (2021)

Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis
por: Guberna, Laura, et al.
Publicado: (2021)

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
por: MIYAMOTO, Shoko, et al.
Publicado: (2022)

Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
por: Song, Joo Hye, et al.
Publicado: (2021)

The evolution of COVID-19: A discontinuous approach
por: Doménech-Carbó, Antonio, et al.
Publicado: (2021)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection
por: Hernández Camba, Alejandro, et al.
Publicado: (2022)

Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection
por: Hernández Camba, Alejandro, et al.
Publicado: (2022)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Case series: Continued remission of PTSD symptoms after discontinuation of prazosin
por: Richardson, Christie, et al.
Publicado: (2023)

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February–April 2020)()
por: Marín-Jiménez, Ignacio, et al.
Publicado: (2020)

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2019)

Can vitamin D induce remission in patients with inflammatory bowel disease?
por: Goulart, Ricardo de Alvares, et al.
Publicado: (2022)

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
por: Buhl, Sine Schnoor, et al.
Publicado: (2014)

Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

D-penicillamine-induced glomerulonephritis with crescent formation: Remission following drug discontinuation
por: Mokuda, S., et al.
Publicado: (2013)

Immunoepigenetic Regulation of Inflammatory Bowel Disease: Current Insights into Novel Epigenetic Modulations of the Systemic Immune Response
por: Bastida, Guillermo, et al.
Publicado: (2023)

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Iron Deficiency Is Common During Remission in Children With Inflammatory Bowel Disease
por: Wikholm, Emma, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1qpe5ft6im9j06d24saq6l7oo4